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Abstract
Objective: The aim of this work was to evaluate the expression of FUT2 gene in saliva and histo ABH antigens of 
patients with oral lesions. 
Study Design: In total 178 subjects were examined, half of whom suffered from oral pre-cancerous and cancerous 
lesions, while the other half were the healthy control group We analyzed the FUT 2 polymorphism by ASO-PCR 
(allele specific oligonucleotid – polymerase chain reaction) with specific primers for G428 allele and the wild type 
allele of FUT2 gene. To reveal A, B and H antigens in tissue sections of the patients (n= 89) we used a modified 
specific red cell adherence technique. 
Results: We found a high intensity of oral disease in the non-secretor group (OR = 2.43). A total of 58% of the 
patients with oral pre-cancerous and cancerous lesions was non secretors (se_/_), in contrast with the healthy 
population (21.5%). A strongly positive reaction was defined as a sheet of indicator erythrocytes adhered to the 
epithelial cells. In 31 of the 54 samples analyzed the test showed slightly positive results on atypical areas, and 
there was a complete antigen deletion in areas affected by neoplasia. Nineteen samples showed a total absence 
of ABH antigens in both histologically normal and pathological areas. Blood group antigens were expressed at a 
high level in benign and highly differentiated malignant tumors. In poorly differentiated malignant tumors, they 
were mostly absent. 
Conclusion: Considering these results we suggest the use of this method to monitor probable preneoplastic lesions 
in risk population, especially in those with no secretor status (absence of FUT2 gene).
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Introduction
Blood group antigens are polymorphic, inherited struc-
tures located on the red blood cell surface (1,2). The 
ABO blood group antigens are among the well-known 
fucosylated glycans. The expression of them is regu-
lated by several glycosyltransferases that add monosac-
charides to a precursor molecule in a sequential fashion 
(3�5). The �(l,2) fucosyltransferase that forms the H 
antigen, an essential precursor of the A and B antigens, 
plays a regulatory role in the tissue expression of the 
ABO antigens. 
The expression and secretion of ABO antigens in epi-
thelial cells are controlled by secretortype �(l,2)fuco�-
syltransferase activity, known as the Secretor (Se) trans-
ferase (FUT2 gene product) (2,6). Several different pol-
ymorphisms are known in the FUT2 gene, some called 
as silent mutations, while others as to non-functional 
enzymes. Homozygous individuals with non-functional 
enzymes are termed non-secretors (se_/_). About 20% 
of individuals are non secretors who fail to express the 
ABO antigen in saliva. On the other hand, heterozygous 
individuals carrying one functional allele, have secre-
tion similar to the wild-type. These are termed secretors 
(Se) (6,7).
The functional significance for ABO antigen e�pression 
on erythrocytes has not been defined, but ABO�related 
structures may play a role in other systems. Alterations 
in the expression of fucosylated oligosaccharides have 
also been observed in several pathological processes, 
including cancer and atherosclerosis (8-10).
In carcinomas, altered expression of the various car-
bohydrate epitopes of this family occur, and are often 
strongly associated with either a good or bad prognosis. 
In human tumors, blood group antigens change in the 
same general direction as other glycosphingolipids do 
in tumors (11,12). The mechanisms of aberrant expres-
sion of blood-group antigens are not clear in all cases 
(13-15). The basis of the changes occurring in cell sur-
face carbohydrate antigens during cellular differentia-
tion and the further changes which occur with malig-
nant transformation appears to be highly complex. It 
has been demonstrated in a number of earlier studies 
on the etiology and pathogenesis of certain diseases that 
the patients' secretor status (ABO (H) blood group anti-
gens) may probably be a factor influencing the develop-
ment of systemic oral diseases (16,17).
The aim of the present study was to evaluate the expres-
sion of FUT2 gene in saliva and histo ABH antigens of 
patients with oral lesions in order to determine whether 
this factor could be a marker risk of oral cancer.
Patients and Methods
The patients analyzed in this study presented to the Sto-
matology Department of the Odontology Faculty of the 
National University of Rosario. Recruitment was made 
by consecutive sampling for a period of 18 months.
From a total of 178 subjects examined, half suffered 
from oral lesions (benign, pre-cancerous and cancer-
ous ones), while the other half were the healthy control 
group. All were subjected to clinical oral examinations 
and standard evaluation tests in order to establish the 
secretor status of their saliva. In the group of patients 
with oral benign, pre-cancerous and cancerous lesions 
(experimental group), a histopathological examination 
of the oral mucosa was performed.
Patients with benign oral lesions showed hyperplasia 
caused by diverse agents such as infectious, inflamma-
tory, traumatic, hormonal, and drugs. The premalignant 
lesions included leukoplakia and lichen planus. The ma-
lignant lesions studied were squamous cell carcinoma. 
All subjects gave informed consent to participate in the 
study, and the protocol was approved by the Ethic Com-
mittee of the School of Medical Sciences of Rosario, 
Argentina, according to the principles of the Declara-
tion of Helsinki.
Serological studies
•  Secretor status: we analyzed their saliva and serum by 
the agglutination inhibition technique (18).
•  Specific red cell adherence test (19)
Slides of 4�5 micron section were deparaffinized and 
brought to water, immersed in tris buffered saline 0.05 
M (pH 7.4) for 30 minutes, covered with isologous an-
tisera according to patients’ blood group and incubated 
for one hour for A, B and O group in a moist chamber 
at room temperature. The slides were then dipped in 
tris buffered saline for three changes with occasional 
strings to remove the unreacted antisera. Few drops of 
2-5% isologous indicator RBC’s suspension were added 
to the sections and incubated for 20 minutes in group 
A or B and one hour for group O. The slides were in-
verted over a support in a petridish containing tris buff-
ered saline such that the undersurface of the slide just 
touched the solution and kept for five minutes to settle 
down unreacted RBCs. The slides were observed under 
the microscope with low power and photographed im-
mediately.
Controls: Normal tissues containing blood group an-
tigens, endothelium of blood vessels and RBCs acted 
as inbuilt positive controls and adipose tissues acted as 
inbuilt negative controls.
Interpretation: In the present study the isoantigenicity 
of epithelium was graded according to degree of adher-
ence of indicator RBCs as strongly positive adherence 
(++++) to negative adherence (-). Levels intermediate 
were determined as 25% of adherence +, 50% of adher-
ence ++ and 75% of adherence +++.
Molecular studies 
DNA isolation
Genomic DNA was isolated from saliva samples. We 
designed a protocol for DNA extraction from these sam-
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ples. They were subjected to thermal shock by succes-
sive freezing and thawing and centrifuged to work with 
the cell button. We used the technique CTAB�DTAB 
(dodecyltrimethylammoniumbromide/ cetyltrimethyl-
ammoniumbromide adding CTAB directly without the 
addition of TE buffer (20,21).
The DNA concentration was measured spectrophoto-
metrically at 260 nm and diluted in sterile water to a 
concentration of 100 ng per µL. 
G428A polymorphism 
The DNA samples were analyzed by ASO-PCR (allele 
specific oligonucleotid – polymerase chain reaction) 
with specific primers (Operon Lab) for G428 allele and 
the wild type allele of FUT2 gene. A fragment of 132 bp 
was amplified as described by Henry et al. (21), e�cept 
for the annealing temperature modifications. According 
to gradient of PCR the Tm of the primers chosen was 
66ºC. The PCR products (132 bp) were analyzed in 2 % 
agarose gel containing ethidium bromide. 
Statistical Analysis 
The categorical data were examined with a 2 test, and 
the ORs were calculated as measure of association. 
Results
In our population the nonsense mutation (428 G�A) in 
the FUT2 gene is the most frequent polymorphism. We 
studied the possible association between the 428 G�A in 
the FUT2 gene and oral disease progression. The geno-
typing revealed that 18 (20.5%) of the 89 blood donors 
were found to be non-secretors (se_/_) and 79.5 % of the 
healthy individuals studied presented the Se gene (FUT 
2) that governs the secretion of water-soluble ABH anti-
gens into saliva (control group). These secreted antigens 
can be demonstrated in saliva by agglutination inhibition 
tests with ABH antisera and molecular biology through 
analysis of the FUT 2 gene. In contrast, twenty-eight 
patients (58%) with oral pre-cancerous and cancerous 
lesions were non secretors, OR = 2.43; CI 95% (1.03; 
5.71) (p= 0.0407) (Table 1). We found a higher intensity 
of oral disease in the non-secretor group, and epithelial 
dysplasia was found exclusively in this group. 
The molecular analysis showed that 48.31% of patients 
was homozygous for the G428A mutation (the mutation 
present in the 2 alleles), while the other patients were 
homozygous for the secretor status (none of them pre-
sented the allele G428A), or heterozygous secretor (1 
allele presented with the mutation G428A) (Fig. 1).
Loss of A, B, and H antigens from the surface of tis-
sue was observed in 31 patients with oral malignancies 
(57,41 %) (Table 2).The other 42,59 % maintained the 
ABH expression (Table 2). Thirty-nine percent of the 
Fig. 1. The agarose gel shows the PCR products of 132 bp for the M1-M6 samples. Each sample was analysed for the wild type 
allele (Se) and for G428A allele (se) and was run together with secretor control (CS) and non�secretor control (CNS).
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histopathologically diagnosed benign lesions lost the 
antigenic reactivity (Fig. 2, 3).
Within the most invasive tumors sites, a deletion of 
ABH reactivity correlated significantly with the stage of 
tumor development and histological malignancy grade. 
In the sections studied, the endothelium of blood ves-
sels was reactive with the erythrocytes (positive con-
trol) and adipose tissues did not react with the red blood 
cells (negative controls).
Discussion
The secretor status is defined by the presence of H type 
1 antigen in body secretions such as milk and saliva. H 
type 1 antigen belongs to both the Lewis and the ABO (H) 
histo-blood-group systems and it is expressed in eryth-
rocyte membranes and in several epithelial tissues. The 
secretor enzyme (FUT2), an ��1,2�fucosyltransferase, is 
responsible for the fucose transfer in an ��1,2 linkage to 
form the terminal H type 1 structure (3–6). The cell�
surface fucosylated oligosacharides participate in sev-
eral biological processes, such as embryogenesis, tissue 
differentiation, tumour metastasis, inflammation and 
bacterial adhesion (15,17). About 20% of the Caucasian 
population is non-secretor (9). Several disease correla-
tions have been linked to non-secretor status. In gen-
eral, being non-secretor results in several disadvantages 
regarding metabolism and immune function (4,8,14). 
Our results have demonstrated that most of the indi-
Benign
Lesions (mucoceles, 
papilloma, etc)
Pre-cancerous + 
Cancerous
FUT2 –Se  
(Secretor Status) 
26 20 
FUT2 –se  
(Non Secretor Status) 
15 28 
Table 1. Secretor status in patients with oral lesions.
Precancerous 
Cancerous 
Benign Lesions 
Parcial or total 
deletion 31 15 
Antigenic
conservation 23 20 
Table 2. Abh antigens e�pression in fi�ed tissue sections of oral le-
sions.
Fig. 2. Cancerous lesion: non inmunoadherence of red blood cells. Fig. 3. Oral benign lesion: inmunoadherence of red blood cells to 
the tissue.
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viduals examined in the healthy group were secretor 
(have the FUT2 gene) (79.5 %) and there were signifi-
cant difference between secretors and non-secretors in 
the experimental group. We have also found a higher 
intensity of oral disease in the non-secretor group, and 
the occurrence of epithelial dysplasia was mostly found 
in the non-secretor group. This study evaluated the as-
sociation between oral lesions and polymorphisms of 
the Se genes. We found that oral pre-cancerous and can-
cerous lesions were increased among individuals with 
non secretor status and nonsense mutation 428G→A 
(Trp143→stop) (58.33%). We found 20 patients diag-
nosed histopathologically as malignant lesions despite 
the secretory status.
The studies of patients with premalignant and malignant 
oral lesions, in which non-secretor status predominates, 
appear to be an associated risk marker for the develop-
ment of oral cancer. Leukoplakia and erythroplakia are 
clinical changes in the oral mucosa regarded as poten-
tially malignant lesions (1,9). Certain histopathological 
changes may indicate a malignant potential in a lesion. 
However, the presence of such changes is not a reliable 
predictor of malignant transformation, and their ab-
sence does not mean that the patient is out of risk of 
developing a tumour (1,13).
Carbohydrate structures were found on the cell surface 
bound to either lipid or protein embedded in the mem-
brane. Changes in the carbohydrate structure of these 
cell-surface glycolipids and glycoproteins have been 
demonstrated during cell maturation development in 
adult tissue, and in relationship with malignant devel-
opment (9-12). Blood-group antigens can be present on 
key receptors controlling cell proliferation, adhesion, 
and motility, such as epidermal growth factor recep-
tor, integrins, cadherins, and CD-44. The patterns of 
expression of these various receptors differ according 
to the type of normal epithelium and the type of cancer, 
and therefore the role of ABH antigens in the biology of 
human cancers may also vary. The function of the ABO 
e�pression in normal stratified oral epithelium is unclear 
(16). Furthermore, the expression of histo-blood-group 
antigens in normal human tissues depends on the type 
of differentiation of the epithelium and the maturation 
degree of the single cell within the epithelium. 
Although the relationship between epithelial dysplasia 
in a leukoplakia and malignant transformation of the le-
sion is debatable, many workers consider that the find-
ing of epithelial dysplasia indicates a higher likelihood 
to develop malignancy. It is, however, more probable 
that the antigen changes found in the dysplastic lesions 
are associated with other factors, such as cell movement 
and growth rate, rather than malignancy per se (10). 
It is generally accepted that tumors are composed of 
heterogeneous cell populations with different biologi-
cal behaviors. To obtain optimal prognostic information 
about the tumor, therefore, the entire tumor cell popula-
tion should be studied. Despite the somewhat unrepre-
sentative biopsy material, it was possible to show that 
loss of ABH antigens were associated with the tumor 
spread (stage). This could be of diagnostic and prog-
nostic value. Similar loss of ABH antigens in bladder 
cancers was associated with a poor prognosis in some 
studies (22,23).
We also observed a reduction or complete deletion 
of A, B or H antigen expression in tissues sections of 
non secretor patients with oral precancerous lesions or 
carcinomas. Disappearance of the antigens is ascribed 
to the absence of A or B transferase gene expression 
(24). These findings are consistent with several studies 
showing that the loss of A and B antigen expression is 
associated with increased tumourigenecity in syngenic 
animals. 
Other study has showed that the sequential e�pression 
of antigen is lost in carcinomas but retained in lesions 
with epithelial dysplasia and in lesions which clinically 
and histologically are regarded as benign. It also showed 
that although the sequential e�pression of carbohydrate 
antigens are retained in lesions with epithelial dysplasia, 
these lesions differ from normal and benign lesions due 
to an extended distribution of one of the carbohydrate 
structures (12). Some findings have also demonstrated 
that malignant development in stratified oral epithelium 
is associated with aberrant glycosylation of cellular 
glycoconjugates and that there are differences between 
premalignant lesions and carcinomas which may prove 
to be of diagnostic significance (12).
To conclude, we propose that areas of SRCA-test nega-
tive epithelium are closely related to invasive carcino-
mas and may be their precursor lesions. In addition, our 
results indicate that at the same time as the morphologi-
cal changes occur during the process of oral carcino-
genesis, another series of events occurs. Further follow-
up studies are required to clarify the role of predictive 
markers of risk in precursor lesions of oral cancer. 
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